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Introduction: Acute basilar artery occlusion (BAO) results in strokes characterized by poor
outcome. Intravenous and intraarterial thrombolysis with rt-PA (IV rt-PA and IA rt-PA,
respectively) and mechanical thrombectomy (MT) are the most commonly used techniques
to treat BAO, but their efﬁcacy remains unclear. Unlike in previous papers, we compared all
three methods of the treatment in a single work, including an update of meta-analysis
regarding each of the three therapeutic approaches with recent trials.
Methods: We systematically reviewed all original studies testing the efﬁcacy of any of the
three basic methods of BAO treatment dated up to the end of Jan 2017.
Results: The ﬁnal analysis included 31 studies that summarized 1358 patients. These sub-
jects were organized into three therapeutic groups: IV rt-PA, IA rt-PA  IV rt-PA, MT  IV rt-
PA  IA rt-PA. The weighted pooled estimates of a favorable outcome (mRS 0–2) were 32.57%
(95% CI 16.44–51.03%/I2 = 67.5%, p = 0.0795) in the ﬁrst group, 22.56% (95% CI 16.85–28.79%/
I2 = 52.1%, p = 0.027) in the second group, and 37.04% (95% CI 32.27–41.92%/I2 = 32%,
p = 0.0895) in the third group. The Q-test subgroup analysis revealed the statistical superi-
ority of MT  IV rt-PA  IA rt-PA over IA rt-PA  IV rt-PA (mRS 0–2: p = 0.0003, mRS 6:
p = 0.0010) and over any rt-PA administration (either IV rt-PA or IA rt-PA  IV rt-PA) (mRS
0–2: p = 0.0006, mRS 6: p = 0.0056).
Conclusions: Current data on the effects of the three basic approaches of the treatment of
BAO are insufﬁcient to generate high-class EBM guidelines. MT seems to be the most
effective method of the treatment of acute BAO. The efﬁcacy of IV or IA thrombolytic
therapy in this indication remains unclear.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Acute basilar artery occlusion (BAO) results in strokes
characterized by poor outcomes and high mortality [1]. The
most commonly applied therapies for acute BAO include
intravenous and/or intraarterial administration of recombi-
nant tissue plasminogen activator (IV rt-PA and IA rt-PA,
respectively) and any-device mechanical thrombectomy (MT).
There are few and rather small trials investigating therapeutic
approaches in acute BAO, which is partially caused by the
relatively low prevalence of this condition [2–32]. Their resultsFig. 1 – Funnel plots for (a) favorable outcome in group 2; (b) favora
in group 3; (e) favorable outcome in groups 1 and 2; and (f) morthave been summarized and meta-analyzed in further studies
[33–35]. These have suggested that mechanical thrombect-
omy, both in monotherapy or in combination with thrombo-
lytic therapy, is the efﬁcient therapeutic option in this type of
stroke, whereas data for the effects of IV rt-PA and IA rt-PA are
much less unequivocal [33–35].
Only a few papers provide an analytical comparison of the
selected two of the three basic methods of BAO treatment, and
no one lists and statistically compares all three in one
dissertation, as per a PubMed search [33–36]. In this study,
we performed meta-analyses of the basic common methods of
the treatment of acute BAO in terms of the functional outcome,ble outcome in group 3; (c) mortality in group 2; (d) mortality
ality in groups 1 and 2.
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between each of the therapeutic approaches. We accommo-
dated all BAO therapeutic trials published or being available
on-line and/or in press by the end of January 2017. These
included several recent articles that have never been taken
into account in any of the previous meta-analyses. We divided
and combined treatment protocols used in these studies into
three groups: 1/lone IV rt-PA, 2/IA rt-PA preceded or not by IV
rt-PA, and 3/any-device MT preceded or not by any route of rt-
PA administration.
2. Materials and methods
2.1. Study search and selection
Two of the authors (SS and DT) have independently reviewed
MEDLINE (PubMed) and SCOPUS databases for suitable papers
published until the end of January 2017, introducing the
following search design: 'basilar [title] AND occlusion [title]
AND treatment' for MEDLINE and 'TITLE (basilar) AND TITLE
(occlusion) AND ALL (treatment)' for SCOPUS. Following this,
the authors identiﬁed the ﬁnal package for the meta-analysis
based on title and abstract reads. Data inconsistencies in theFig. 2 – PRISMA flow diagram representing seaselection of articles between reviewers were discussed and
resolved by mutual consensus. The full texts of the selected
papers were then carefully analyzed and used to do the meta-
analyses.
2.2. Eligibility criteria
In the ﬁnal analysis, we included observational or interven-
tional studies, regardless of the project design, published in
English, performed in an adult population, covering data about
a minimum of 10 patients treated due to acute BAO, and
reporting a 3-month assessment of the functional outcome by
modiﬁed Rankin Scale (mRS) [37]. We excluded studies testing
methods of the BAO treatment other than intravenous or
intra-arterial thrombolysis with recombinant tissue plasmin-
ogen activator (rt-PA) and mechanical thrombectomy or their
combinations. The main outcome measures included disabili-
ty (mRS score 3 months after stroke onset) and mortality.
2.3. Treatment strategies and compared groups
We divided the selected BAO therapeutic trials and series'
descriptions into three groups. The ﬁrst included all studies
testing the efﬁcacy of intravenous thrombolysis alone (group 1:rch strategy for the systematic review [39].
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were treated with intra-arterial thrombolysis, either alone or
in combination with intravenous thrombolysis in any IV/IA rt-
PA dose proportion (group 2: IV rt-PA  IA rt-PA). The third
group included studies in which patients were treated with
mechanical thrombectomy, regardless of the device used,
preceded or not with administration of rt-PA either IV or IA
regardless of the dose (group 3: MT  IA rt-PA  IV rt-PA).
Taking into account the small number of studies in group 1,
we expanded our analysis by combining groups 1 and 2 into
one, thus comparing effects of any rt-PA treatment (either IV or
IA or combined) with thrombectomy.
2.4. Summary measures
The main endpoint of this study was a 3-month mRS score,
independent of other measures of the treatment, like
recanalization or reperfusion. The favorable outcome was
deﬁned as mRS score 0–2 (patients functionally independent).
We have also performed an extra meta-analysis for mortality
(3-month survivors versus deaths). Percentages and 95%
conﬁdence intervals were estimated for each study, as was
the overall effect.Fig. 3 – Forest plots for (a) favorable outcome in group 1; (b) favora
mortality in group 1; (e) mortality in group 2; (f) mortality in grou
(h) mortality in group 1 and 2 combined.2.5. Statistical analysis
To establish variance of individual studies, we applied the
Freeman-Tukey double arcsine transformation. The meta-
analysis was based on a random effects model, where we
applied a combination of DerSimonian and Laird model with
transformed proportions. Ultimately, overall effects were
back-transformed. The 95% conﬁdence intervals of the
estimates were performed using the Wilson method with
continuity correction. Heterogeneity was assessed using the I2
statistic and Q test. Overall effects for a favorable outcome, as
well as for mortality, were compared using the Q-test based on
analysis of variance [38]. All analyses were performed using
the meta package for R V3.2.3. The signiﬁcance threshold was
set at .05.
The possibility of publication bias was evaluated by visual
analysis of a funnel plot, the Begg and Mazumdar's rank
correlation test, and the Egger's linear regression.
2.6. Comparison between the three therapeutic approaches
We compared the functional outcome and mortality between
each of the three therapeutic approaches (groups 1, 2, and 3)ble outcome in group 2; (c) favorable outcome in group 3; (d)
p 3; (g) favorable outcome for groups 1 and 2 combined; and
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For this purpose, we assumed that the set of meta-analyses for
the selected end-points (functional outcome, mortality) will
constitute a set of the subgroups. This approach is commonly
used in the subgroups analysis, although it does have some
important limitations [38].
3. Results
3.1. Study characteristics
Application of the given criteria through the two databases
resulted in identiﬁcation of 308 records. Following elimination
of duplicates (including different analyses – papers based on
the same treated populations) and screening of the titles and
abstracts, the list of articles shortened to 57 items. Full texts of
the latter were carefully read by two independent authors,Fig. 3. (Contwho ﬁnally selected 31 studies with 1358 subjects to be
included in the review and meta-analyses (Fig. 2). MT devices
used in the selected studies included Solitaire, Trevo, Catch,
Phenox, Angio jet Ultra, ReVive, Penumbra.
Among the analyzed studies, nine were prospective single-
center trials, ﬁfteen were retrospective single-center trials, and
the remaining six were retrospective multicenter studies.
Characteristics of the included articles are shown in Tables 3–5.
3.2. Functional outcome and mortality
The weighted pooled estimates of the favorable outcome (mRS
0–2 at 3 months) were 32.57% (95% CI 16.44–51.03%/I2 = 67.5%,
p = 0.0795) in the ﬁrst group, 22.56% (95% CI 16.85–28.79%/
I2 = 52.1%, p = 0.027) in the second group, and 37.04% (95% CI
32.27–41.92%/I2 = 32%, p = 0.0895) for the third group (Fig. 3).
The mortality rates (mRS 6 at 3 months) were 25.00% (95% CI
4.80–53.03%/I2 = 88.7%, p = 0.0001) in group 1, 42.79% (95% CIinued ).
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CI 19.24–30.13%/I2 = 53.1%, p = 0.0043) for the third group
(Fig. 3).
The Q-test subgroup analysis revealed the statistical
superiority of the mechanical thrombectomy (MT  IV rt-PA
 IA rt-PA: group 3) over IA rt-PA  IV rt-PA (group 2) (mRS
0–2: p = 0.0003, mRS 6: p = 0.0010) and over any rt-PA
administration (either IV rt-PA or IA rt-PA  IV rt-PA: com-
bined groups 1 + 2) (mRS 0–2: p = 0.0006, mRS 6: p = 0.0056)
(Table 1). Current data on speciﬁc BAO treatment are
insufﬁcient to assess the superiority between MT (MT  IV
rt-PA  IA rt-PA: group 3) and IV rt-PA (group 1) or between IAFig. 3. (Contrt-PA  IV rt-PA (group 2) and IV rt-PA (group 1) due to low
number of reported patients in the latter (Table 1).
The weighted pooled estimate of a favorable outcome (mRS
0–2) for the effects of any rt-PA treatment (IA and/or IV;
combined groups 1 and 2) was 24.18% (95% CI 18.95–29.80%/
I2 = 53%, p = 0.0156), whereas the mortality rate (mRS 6) was
39.09% (95% CI 30.50–48.01%/I2 = 80%, p < 0.0001).
3.3. Publication bias across studies
We found no evidence of publication bias in the funnel plot,
the Begg and Mazumdar's rank correlation test, and the Egger'sinued ).
Fig. 3. (Continued ).
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the risk of bias across studies is presented in Fig. 1. However, of
note is that the number of studies in the ﬁrst group (IV rt-PA)
was insufﬁcient to explore the bias across them.
4. Discussion
This is a ﬁrst work showing meta-analyses for the
functional outcome of all three basic methods of the
treatment of BAO, followed by a comparison between these
approaches.The main end-point for the analysis was deﬁned as mRS 0–
2, and the secondary end-point was survival, both after 3
months, with no extra variables, such as Barthel's Index or
Glasgow Outcome Scale, used in some studies.
Our systematic review revealed that current empirical and
observational data on the effects of the three basic approaches
of the treatment of acute BAO are insufﬁcient to generate high-
class evidence-based medicine guidelines. Among the records
shortlisted for this meta-analysis, there was no single
randomized clinical trial. Interestingly, manually the easiest
and the most available IV rt-PA had the poorest empirical
information, summing up to only 2 studies (when considering
Table 1 – Results of the Q-test (comparison between three therapeutic approaches).
Comparison Q statistic Degree of freedom (df) P value
Favorable outcome groups 1 vs. 2 vs. 3 13.005 2 0.0015
Favorable outcome groups 1 vs. 2 1.136 1 0.2864
Favorable outcome groups 2 vs. 3 13.004 1 0.0003
Favorable outcome groups 1 vs. 3 0.239 1 0.6246
Mortality groups 1 vs. 2 vs. 3 10.992 2 0.0041
Mortality groups 1 vs. 2 1.452 1 0.2283
Mortality groups 2 vs. 3 10.869 1 0.0010
Mortality groups 1 vs. 3 0.0007 1 0.979
Favorable outcome groups 1 and 2 vs. 3 11.790 1 0.0006
Mortality groups 1 and 2 vs. 3 7.680 1 0.0056
Table 2 – Results of Begg and Mazumdar's test and Egger's test for groups 2–3.
Outcome Begg and Mazumdar's test Egger's test
Favorable outcome group 1 – –
Favorable outcome group 2 p = 0.5312 p = 0.6239
Favorable outcome group 3 p = 0.5281 p = 0.5588
Favorable outcome group 1 and 2 p = 0.7311 p = 0.8919
Mortality group 1 – –
Mortality group 2 p = 0.6971 p = 0.6742
Mortality group 3 p = 0.5949 p = 0.3528
Mortality group 1 and 2 p = 0.7007 p = 0.7941
Table 3 – Characteristics of studies included in group 1.
Reference Study period Study design Patients
(n)
Mean
age (years)
Favorable
outcome
(mRS 0–2) (%)
Mortality
(%)
Median time
to therapy (h)
Miyagi et al. [2] 2005–2008 R, multicenter 25 70 44 4 2.5
Sairanen et al. [3]a 1995–2008 P, single-center 116 63 26 41 8.7
Pagola et al. [4] – P, – 20 67 – 35 3
mRS – modiﬁed Rankin Scale score; P – prospective; R – retrospective.
a 7/116-I-A.
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were both retrospective and prospective, with a relatively
small number of patients in each group, which carries a risk of
publication bias and might overestimate outcome effects.
Despite those preliminary limitations, this analysis carries
useful information. The percentage of favorable-outcome
patients after IV rt-PA was 32.57%, whereas following IA rt-
PA (preceded or not by IV rt-PA), it was 22.56%. In a former
meta-analysis by Lindsberg and Mattle [36], application of
thrombolysis, either intravenous or intra-arterial, had compa-
rable results regarding good outcome (22% and 24%, respec-
tively) and obviously differed to the numbers revealed in our
meta-analysis, mainly due to fewer studies being taken into
account and different methodological approaches.
These current data provide a higher class of evidence for
the superiority of the use of endovascular mechanical devices.
The mechanical thrombectomy with the use of any endovas-
cular device, preceded or not by any rt-PA administration, is
the most efﬁcient therapeutic method for this condition if
measured by functional outcome and mortality. In our meta-
analysis, this approach was better than two others (separatelyor combined), reaching the highest pooled estimate of
favorable outcome and the lowest mortality rate.
The Q-test subgroup analysis revealed that the mechanical
thrombectomy in BAO preceded or not by rt-PA administration
(group 3) is superior to IA rt-PA preceded or not by IV rt-PA
(group 2) and to any rt-PA administration (either IV rt-PA or IA
rt-PA: combined groups 1 + 2). However, this analytical
method, although frequently used for similar comparisons,
has some limitations and must be treated with caution [38].
Previous systematic reviews [33–35] have also demonstrat-
ed lower rates of mortality and higher likelihood of favorable
outcome in acute BAO when mechanical thrombectomy was
applied.
There are several basic variables that might inﬂuence the
results of the effect of each of the therapeutic approaches. For
example, IV rt-PA, IA rt-PA, and MT might have different
efﬁciencies in different time windows after stroke. However,
the authors assessing full texts of the papers (eligibility step of
the systematic review) did not ﬁnd sufﬁcient data regarding
the time from stroke onset to therapeutic intervention to be
able to take them into account in the meta-analyses.
Table 4 – Characteristics of studies included in group 2.
Reference Study period Study design Patients
(n)
Mean
age (years)
Favorable
outcome
(mRS 0–2) (%)
Mortality
(%)
Median
time to
therapy (h)
Arnold et al. [5] 1992–2002 R, multicenter 40 58 35 43 5.5a
Bergui et al. [6] 2003–2004 P, single-center 12 64 25 33 7
Eom et al. [7] 2006–2013 R, multicenter 25 67 8 68 5
Haussen et al. [8] 2007–2012 R, multicenter 28 64 18 64 7
Ottomeyer et al. [9]b 2002–2009 R, single-center 91 63 22 42 6.6a
Barlinn et al. [10] 2002–2007 P, single-center 20 62 15 45 5
Jung et al. [11] 1992–2010 P, single-center 106 62 33 41 5.5
Nagel et al. [12] 1998–2006 P, single-center 75 68 13 56 5
Raphaeli et al. [13] – R, single-center 24 55 33 33 –
Chang et al. [14] 2007–2014 R, single-center 59 70 25 14 –
Xianxian et al. [15] – R, single-center 50 – – 40 –
mRS – modiﬁed Rankin Scale score; P – prospective; R – retrospective.
a Mean.
b 9/91-IV.
Table 5 – Characteristics of studies included in group 3.
Reference Study period Study design Patients
(n)
Mean
age (year)
Favorable
outcome
(mRS 0–2) (%)
Mortality
(%)
Median
time to
therapy (h)
Monhlenbruch et al. [16] 2009–2012 P, single-center 24 70b 33 29 4.2
Singer et al. [17] 2011–2013 R, multicenter 148 71b 34 35 –
Wang et al. [18] 2011–2013 R, single-center 18 60 33 28 3.2
Fahed et al. [19] 2006–2015 R, single-center 34 62 32 29 –
Carneiro et al. [20] 2012–2014 R, single-center 24 57 21 33 –
Eom et al. [7] 2006–2013 R, multicenter 32 68 22 25 4.7a
Espinosa de Rueda et al. [21] 2010–2012 R, single-center 18 68 50 22 6.1a
Gilberti et al. [22] 2010–2015 R, single-center 32 64 41 25 7.7a
Huo et al. [23] 2012–2015 P, single-center 36 59 28 31 7.5
Park et al. [24] 2013–2015 R, single-center 12 64 58 0 6
Yoon et al. [25] 2010–2015 R, single-center 50 71b 54 12 4.6
Broussalis et al. [26] 2005–2012 P, single-center 44 68 48 9 4
Mourand et al. [27] 2009–2011 P, single-center 31 61 35 32 6
Andersson et al. [28] 2005–2010 R, single-center 28 – 57 21 –
Mordasini et al. [29] 2010–2011 R, single-center 14 65b 29 36 6.9
Chang et al. [14] 2007–2014 R, single-center 33 – 36 15 –
Werner et al. [30] 2008–2013 R, single-center 22 60b 41 41 4.3
Du et al. [31] 2011–2014 R, single-center 21 58 38 33 –
Shu et al. [32] 2007–2015 R, single-center 46 – 28 – –
mRS – modiﬁed Rankin Scales score; P – prospective; R – retrospective.
a Mean.
b Median.
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therapies into three groups only. The ‘‘bridging therapy’’
(application of IV rt-PA prior to IA rt-PA or any or both of the
two prior to MT), and the MT device construction, might
inﬂuence the outcome, which was intentionally ignored in
this analysis to obtain more reliable (including larger groups)
data for the statistical workout. Finally, there are a lot of
other factors ignored in the analyzed studies that might
inﬂuence outcome after stroke such as for example blood
pressure values in the early phase [40], brain and bodytemperatures [41–43], or various metabolic conditions and
genetic variants [44].
In conclusion, the stent-retriever mechanical thrombecto-
my seems to be the most effective method of treatment of BAO,
showing a good safety proﬁle. The efﬁcacy of intravenous
thrombolytic therapy remains unclear among others due to the
insufﬁcient number of studies and high heterogeneity across
studies. Randomized controlled trials or large high-class
observational studies are required to deliver unbiased data
about the treatment of patients with basilar artery occlusion.
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